Laddar populära aktier...
Minor estimate revisions Subscription business performed well.
After a soft Q3, PMD Device Solutions (“PMD”) is still aiming for a cash break-even by late 2024 or ...
AcuCort har publicerat bolagets delårsrapport för det tredje kvartalet 2024 och annonserat en företr...
Ytterst positivt studieresultat Efter kvartalets slut meddelade bolaget att fas 1b-studien med STA36...
The US company is both a health insurance and a health care service provider covering more than 10m ...
Ramlösa shipping AB (”Ramlösa” eller ”Bolaget”) har hållit ett högt affärstempo under det tredje kva...
Redeye comments on Gapwaves' joint venture agreement with Bosch and revised its estimates and fair v...
Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controll...
VBG Group rapporterade en organisk tillväxtminskning på 11,5 % jämfört med Q3-23, med en omsättning ...
Tangiamo Touch Technology (”Tangiamo” eller ”bolaget”) publicerade den 29 november 2024 bolagets del...
Q3 sales are down by 12% compared with Q3 2024 and by some 35% compared with the previous quarter at...
The positive results in Nanexa’s Phase I study for NEX-22, a once-monthly depot formulation of the G...
Sales SEK 49m (ABGSCe 79m), EBIT -8m (ABGSCe +1m) Slower recovery, flat sales expected in future qua...
Redeye returns following Elicera's Q3 report and recent news in the company.
Redeye updates its view on Verve Group following its Q3 2024 report, which showed strong growth, as ...